← Eichor
Study identifier: NCT04197921 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Condition: Opioid-use Disorder · Substance Use Disorders  ·  Sponsor: InSightec

PhaseNA
Planned participants29
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersYes

About this study

The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and/or other Substance Use Disorders (SUDs) by assessing its safety and tolerability in subjects with OUD.

This description comes directly from the study's public registry record.

Talk to the study team

Kingsley Nwaogu  ·  2143048264  ·  clinicalresearchquestions@insightec.com

Julia Zhu  ·  clinicalresearchquestions@insightec.com

Always discuss trial participation with your own doctor first.

Locations (4)

Tampa General HospitalTampa, Florida, United StatesNot Yet Recruiting
University of Maryland, BaltimoreBaltimore, Maryland, United StatesRecruiting
Weill Cornell MedicineNew York, New York, United StatesRecruiting
West Virginia University: Rockefeller Neuroscience InstituteMorgantown, West Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04197921